Overview

  • Product name
    2,3-Butanedione 2-monoxime (BDM)
  • Description
    Non-selective myosin ATPase inhibitor
  • Alternative names
    • BDM
    • Biacetyl monoxime
    • Diacetyl monoxime
  • Biological description
    Non-selective myosin ATPase inhibitor (Ki = 5 mM at myosin II). Potent Kv2.1 (DRK1) and L-Type Ca2+ channel inhibitor (Ki and IC50 values are 10.7 nM and 5.8 mM, respectively). Blood-brain barrier permeable. Inhibits muscle contraction.

Properties

References

This product has been referenced in:
  • Artigas P  et al. 2,3-butanedione monoxime affects cystic fibrosis transmembrane conductance regulator channel function through phosphorylation-dependent and phosphorylation-independent mechanisms: the role of bilayer material properties. Mol Pharmacol 70:2015-26 (2006). Read more (PubMed: 16966478) »
  • Ostap EM 2,3-Butanedione monoxime (BDM) as a myosin inhibitor. J Muscle Res Cell Motil 23:305-8 (2002). Read more (PubMed: 12630704) »
  • Smith PA  et al. Block of ATP-sensitive K+ channels in isolated mouse pancreatic beta-cells by 2,3-butanedione monoxime. Br J Pharmacol 112:143-9 (1994). Read more (PubMed: 8032636) »

See 0 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab120616.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up